NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach

Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.  

Emerging Company Profile: NextPoint Therapeutics
PD-L1 Negative Cancer Patients Have Fewer Treatment Options • Source: Shutterstock

NextPoint Therapeutics believes it can advance the next big breakthrough in precision immuno-oncology by targeting HHLA2, an antigen commonly expressed in the tumors of the underserved population of PD-L1 negative cancer patients.

The firm was founded in 2018 by two reputed academics with strong track records: Gordon Freeman of the Dana-Farber Cancer Institute, who helped discover the PD-L1 pathway, and XingXing Zang...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Emerging Company Profiles

More from Start-Ups & SMEs